

## 1      Claims

2

3      1. The use of (i) a naked binding member which  
4      binds to both SCR1 and SCR2 of CD55 or (ii) a  
5      nucleic acid encoding said binding member in the  
6      preparation of a medicament for the neutralisation  
7      of CD55.

8

9      2. The use of (i) a naked binding member which  
10     binds to both SCR1 and SCR2 of CD55 or (ii) a  
11     nucleic acid encoding said binding member in the  
12     preparation of a medicament for the enhancement of  
13     complement deposition on a tissue.

14

15     3. The use of (i) a naked binding member which  
16     binds to both SCR1 and SCR2 of CD55 or (ii) a  
17     nucleic acid encoding said binding member in the  
18     preparation of a medicament for treating cancer.

19

20     4. The use according to claim 3 wherein the cancer  
21     is one or more of colorectal, breast , ovarian,  
22     cervical, gastric, lung, liver, skin and myeloid  
23     (e.g. bone marrow) cancer.

24

25     5. The use according to any one of the preceding  
26     claims wherein the binding member is an antibody or  
27     a fragment thereof.

28

29     6. The use according to any one of the preceding  
30     claims wherein the binding member binds to amino  
31     acids 83-93and SCR2 amino acids 101-112 and amino  
32     acids 145-157 of the sequences shown in Figure 1b.

1       7. The use according to any one of the preceding  
2       claims wherein the binding member comprises one or  
3       more of the CDRs of the antibody, or a fragment  
4       thereof, produced by the cell line deposited at ATCC  
5       under accession number HB9173.

6

7       8. The use according to any one of the preceding  
8       claims wherein the binding member is the antibody  
9       791T/36 produced by the hybridoma cell deposited at  
10      ATCC under accession number HB9173.

11

12      9. The use according to any one of claims 1 to 7  
13      wherein the binding member comprises at least one  
14      human constant region.

15

16      10. A naked binding member which binds to both SCR1  
17      and SCR2 for use in the treatment of cancer.

18

19      11. A naked binding member, which binds to both  
20      SCR1 and SCR2 of CD55, and an active agent as a  
21      combined preparation for simultaneous, separate or  
22      sequential use in the treatment of cancer.

23

24      12. The combined preparation according to claim 11,  
25      wherein said active agent is a Doxorubicin, taxol,  
26      5-Fluorouracil, Irinotecan or Cisplatin.

27

28      13. The combined preparation according to claim 11  
29      wherein said active agent is an antibody.

30

31      14. The combined preparation according to claim 13  
32      wherein said active agent is an anti-CD20 antibody;

1       an anti-VEGF antibody; an anti-CD171A antibody; an  
2       anti-CEA anti-idiotypic mAb; an anti-EGFR antibody;  
3       an anti-HMFG anti-idiotypic mAb; an anti-EGFR  
4       antibody, or an anti-HER2 antibody e.g. Herceptin,  
5       Genentech (South San Francisco, CA, USA).

6

7       15. The naked binding member according to any one  
8       of claims 10 to 11, or the combined preparation  
9       according to any one of claims 12 to 14 wherein the  
10      naked binding member is as defined in any one of  
11      claims 1 to 9.

12

13      16. A pharmaceutical composition for the treatment  
14      of cancer, wherein the composition comprises a naked  
15      binding member that binds to both SCR1 and SCR2 of  
16      CD55 and a pharmaceutically acceptable excipient,  
17      diluent or carrier.

18

19      17. The pharmaceutical composition according to  
20      claim 16, wherein the naked binding member is as  
21      defined in any one of claims 1 to 9.

22

23      18. A method of neutralisation of CD55, comprising  
24      administration of a naked binding member which  
25      specifically binds to SCR1 and SCR2 of CD55.

26

27      19. A method of enhancing complement deposition  
28      comprising administration of a naked binding member  
29      which specifically binds to SCR1 and SCR2 of CD55.

30

31      20. A method of treating cancer comprising  
32      administration of a therapeutically effective amount

1       of a naked binding member which specifically binds  
2       to SCR1 and SCR2 of CD55 to a mammal in need  
3       thereof.

4

5       21. A method according to any one of claims 16 to  
6       18 wherein the naked binding member is as defined in  
7       any one of claims 1 to 9.

8

9       22. An assay method for identification of an agent  
10      capable of inhibiting CD55 comprising step:

11

- 12      a) bringing into contact a candidate agent with at  
13       least a portion of SCR1 and SCR2 of CD55; and  
14  
15      b) determining binding of said candidate agent to  
16       both SCR1 and SCR2.

17

18       23. An assay method for identification of an agent  
19       capable of inhibiting CD55 comprising:

20

- 21      (a) bringing into contact a candidate agent with at  
22       least a portion of SCR1 and SCR2 of CD55 in the  
23       presence of a naked binding member which in the  
24       absence of the candidate agent is capable of  
25       binding both SCR1 and SCR2 of CD55; and  
26  
27      (b) determining the extent to which the candidate  
28       agent inhibits binding of the naked binding  
29       member to SCR1 and SCR2 of CD55.

30

1       24. The assay method according to claim 23 wherein  
2       the binding member is as defined in any one of  
3       claims 6 to 9.

4

5       25. The assay method according to any one of claims  
6       22 to claim 24 further comprising step (c) selecting  
7       a candidate agent which bind both SCR1 and SCR2 of  
8       CD55; and/or step (d) determining the amount of  
9       complement deposition on a cell sample in the  
10      presence and absence of the candidate agent.

11

12      26. The assay method according to any one of claims  
13      22 to 25 wherein said portion of SCR1 and SCR2 of  
14      CD55 comprises amino acids 83-93, 101-112 and 145-  
15      157 of the sequences shown in Figure 1b.

16

17      27. Use of an agent identified by the assay method  
18      of any one of claims 22 to 26 in the manufacture of  
19      a medicament for the treatment of cancer.

20

21